MSLN and neoplasm: A previous study reported that combination of anti-mesothelin CAR-T cells with PD-L1 CAR-T cells did not repress tumor growth synergistically in patient-derived xenograft (PDX) because PD-L1 CAR-T killed mesothelin CAR-T cells by targeting its endogenous PD-L1 antigen.37